Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003

Johansson, S. G. O.; Bieber, Thomas; Dahl, Ronald; Friedmann, Peter S.; Lanier, Bob; Lockey, Richard F.; Motala, C.; Martell, José Antonio Ortega; Platts-Mills, Thomas A.E.; Ring, Johannes; Thien, Francis; Cauwenberge, Paul Van; Williams, Hywel C

doi:10.1016/j.jaci.2003.12.591

Cited by 1,968 publications

(1,184 citation statements)

References 38 publications

Supporting

Mentioning

1,067

Contrasting

Unclassified

Order By: Relevance

“…Results appear especially consistent for eczema 20 within the first year of life. Randomized, controlled trials of nutritional interventions with hydrolyzed formulas on allergic outcomes in adolescence, including asthma, hay fever/allergic rhinitis (AR) and eczema, are scarce 21 or have used a multifaceted approach that combined nutritional and aeroallergen avoidance measures 22, 23, 24.…”

mentioning

confidence: 64%

Allergic manifestation 15 years after early intervention with hydrolyzed formulas – theGINIStudy

Berg

Filipiak-Pittroff

Schulz

et al. 2015

Allergy

View full text Add to dashboard Cite

BackgroundData on the long‐term impact of hydrolyzed formulas on allergies are scarce.ObjectiveTo assess the association between early intervention with hydrolyzed formulas in high‐risk children and allergic outcomes in adolescence.Methods GINI trial participants (n = 2252) received one of four formulas in the first four months of life as breastmilk substitute if necessary: partial or extensive whey hydrolyzate (pHF‐W, eHF‐W), extensive casein hydrolyzate (eHF‐C) or standard cow′s milk formula (CMF) as reference. Associations between these formulas and the cumulative incidence and prevalence of parent‐reported physician‐diagnosed asthma, allergic rhinitis (AR) and eczema, as well as spirometric indices and sensitization, were examined using generalized linear models.ResultsBetween 11 and 15 years, the prevalence of asthma was reduced in the eHF‐C group compared to CMF (odds ratio (OR) 0.49, 95% confidence interval (CI) 0.26–0.89), which is consistent with the spirometric results. The cumulative incidence of AR was lower in eHF‐C (risk ratio (RR) 0.77, 95% CI 0.59–0.99]) and the AR prevalence in pHF‐W (OR 0.67, 95% CI 0.47–0.95) and eHF‐C (OR 0.59, 95% CI 0.41–0.84). The cumulative incidence of eczema was reduced in pHF‐W (RR 0.75, 95% CI 0.59–0.96) and eHF‐C (RR 0.60, 95% CI 0.46–0.77), as was the eczema prevalence between 11 and 15 years in eHF‐C (OR 0.42, 95% CI 0.23–0.79). No significant effects were found in the eHF‐W group on any manifestation,nor was there an effect on sensitization with any formula.ConclusionIn high‐risk children, early intervention using different hydrolyzed formulas has variable preventative effects on asthma, allergic rhinitis and eczema up to adolescence.

show abstract

mentioning

confidence: 64%

Allergic manifestation 15 years after early intervention with hydrolyzed formulas – theGINIStudy

Berg

Filipiak-Pittroff

Schulz

et al. 2015

Allergy

View full text Add to dashboard Cite

show abstract

“…3). Anaphylaxis mediated by immunoglobulin (Ig)E, IgG, complement, or immune complexes is defined as immune‐mediated anaphylaxis, as opposed to non‐allergic anaphylaxis (previously known as an anaphylactoid reaction) 15. Immune‐mediated anaphylaxis is further divided into IgE‐ and non IgE‐mediated types.…”

Section: Mechanisms Of Anaphylaxismentioning

confidence: 99%

Drug‐induced anaphylaxis in the emergency room

Takazawa

Oshima

Saito

2017

Acute Medicine & Surgery

View full text Add to dashboard Cite

Anaphylaxis is a life‐threatening, systemic allergic reaction that presents unique challenges for emergency care practitioners. Anaphylaxis occurs more frequently than previously believed. Therefore, proper knowledge regarding the epidemiology, mechanisms, symptoms, diagnosis, and treatment of anaphylaxis is essential. In particular, the initial treatment strategy, followed by correct diagnosis, in the emergency room is critical for preventing fatal anaphylaxis, although making a diagnosis is not easy because of the broad and often atypical presentation of anaphylaxis. To this end, the clinical criteria proposed by the National Institute of Allergy and Infectious Diseases and the Food Allergy and Anaphylaxis Network are useful, which, together with a differential diagnosis, could enable a more accurate diagnosis. Additional in vitro tests, such as plasma histamine and tryptase measurements, are also helpful. It should be emphasized that adrenaline is the only drug recommended as first‐line therapy in all published national anaphylaxis guidelines. Most international anaphylaxis guidelines recommend injecting adrenaline by the intramuscular route in the mid‐anterolateral thigh, whereas i.v. adrenaline is an option for patients with severe hypotension or cardiac arrest unresponsive to intramuscular adrenaline and fluid resuscitation. In addition to the route of administration, choosing the appropriate dose of adrenaline is essential, because serious adverse effects can potentially occur after an overdose of adrenaline. Furthermore, to avoid future recurrence of anaphylaxis, providing adrenaline auto‐injectors and making an etiological diagnosis, including confirmation of the offending trigger, are recommended for patients at risk of anaphylaxis before their discharge from the emergency room.

show abstract

“…[1] A systematic review of the published evidence for allergic sensitisation and dermatitis in 12 population studies worldwide has shown that IgE hyper-responsiveness does not necessarily equate to AD, even though it may be associated with the disease phenotype, especially in severe disease. [2,11] Geographical location was associated with the risk of being atopic among those with AD compared with normal healthy controls.…”

Section: Allergic Sensitisationmentioning

confidence: 99%

“…According to the position paper of the Nomenclature Review Committee of the World Allergy Association, [1] the term atopic eczema/dermatitis syndrome (AEDS) should be used as the umbrella term covering the different subtypes of AD. The new nomenclature (AEDS) underlines that AD is not one single disease entity, but rather an aggregation of several diseases that have certain clinical characteristics in common.…”

mentioning

confidence: 99%